Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics

被引：17

作者：

Bailey, Alexandra ^{[1
,2
]}

McDermott, David F. ^{[2
,3
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Beth Israel Deaconess Med Ctr, Biol Thrapy Program, Boston, MA 02215 USA

来源：

CANCER JOURNAL | 2013年 / 19卷 / 04期

关键词：

Checkpoint inhibitor; immunotherapy; programmed death 1 (PD-1); programmed death ligand 1 (PDL-1); cytotoxic T-lymphocyte antigen 4 (CTLA-4);

D O I：

10.1097/PPO.0b013e31829e3153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies targeting programmed death 1, programmed death ligand 1, and cytotoxic T-lymphocyte antigen 4 pathways are currently in development for metastatic renal cell carcinoma. By inhibiting these immune regulatory pathways, these agents improve the immune response to cancer with the goal of creating durable responses. Although still early in development, several agents have been studied in phases I and II setting for metastatic renal cell carcinoma, with 1 drug in phase III testing (nivolumab). The unique toxicity profile of this class of therapy presents challenges to the treating clinician. Ongoing clinical trials hope to define patients who will benefit based on predictive biomarkers. Immune checkpoint inhibitors may play a key role in the future of management of solid tumors including kidney cancer.

引用

页码：348 / 352

页数：5